Sanofi SA vs ZIM Integrated Shipping Services Ltd — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while ZIM Integrated Shipping Services Ltd trades at $29.99 (market cap $3.65B). The key difference: Sanofi SA is far larger — about 26.1× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| SNY | ZIM | |
|---|---|---|
Market Cap | $95.18B | $3.65B |
Volume | 2,995,646 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $52.34 | $30.51 |
52-Week Low | $39.51 | $12.44 |
Typical Hold Time | 94 Days | 27 Days |
Enterprise Value | $114.48B | $7.32B |
Dividend Yield | 6.01% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
ZIM trades at $29.99, near its 52-week high of $30.96, reflecting strong momentum. The stock shows a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.53 versus a forecasted loss, driven by higher freight rates and volumes. Revenue for 2026 is projected at $6.4B with a net income margin of 2.15%. The company faces a pivotal moment with Hapag-Lloyd's acquisition offer under Israeli government review.
The outlook is mixed: operational improvements and record transpacific rates offer upside, but merger uncertainty caps near-term gains. Risks include deal rejection, competitive pressures, and volatile shipping rates. Analysts are cautious, with 67% hold ratings, signaling wait-and-see sentiment amid the acquisition saga.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →